Novo Nordisk and Lilly are cutting prices on weight loss drugs like Ozempic, Wegovy, and Zepbound due to competition and agreements. Discounts now available for cash buyers and some Medicare/Medicaid recipients.
Novo Nordisk is reducing prices for Ozempic and Wegovy, offering a $199/month introductory price and lowering the 'typical' cost to $349/month. This makes them competitive with Lilly's Zepbound.
Eli Lilly will manufacture its orforglipron GLP-1 weight-loss pill in the US, avoiding tariffs and aligning with the 'Make America Healthy Again' initiative. Production aims for global availability by 2026. Orforglipron treats diabetes and promotes weight loss.
